Showing results 1 to 20 of 68
next >
| Publication Date | Title | Author(s) |
| Aug-2019 | Citizen brief: Achieving greater impact from investments in medicine in Canada | Waddell, K; Moat, KA; Lavis, JN; Gauvin, François-Pierre |
| Jul-2016 | Citizen brief: Defining the mental health and addictions ‘basket of core services’ to be publicly funded in Ontario | Waddell, K; Bullock, H; Lavis, JN |
| Mar-2020 | Citizen brief: Engaging patients, families and caregivers to support Ontario Health Teams | Gauvin, François-Pierre; Waddell, K; Dion, A; Lavis, JN; Abelson, J; Bullock, H |
| Feb-2019 | Citizen brief: Preventing and managing infectious disease among people who inject drugs in Ontario | Waddell, K; Sharma, K; Wilson, MG |
| Apr-2020 | COVID-19 rapid evidence profile # 2: What is known about the spread and management of COVID-19 in non-health workplaces? | Waddell, K; Gauvin, François-Pierre; Wilson, MG; Moat, KA; Mansilla, C; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #10: What screening approaches can be used in non-healthcare settings (e.g., universities, stores and office settings) to identify people who may have COVID-19 and need to take appropriate action? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Lavis, JN |
| May-2020 | COVID-19 rapid evidence profile #11: What is the evidence related to playground equipment and risk of COVID-19 transmission? | Waddell, K; Wilson, MG; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Voorheis, P; Bhuiya, AR; Ahmad, A; Sharma, K; Lavis, JN |
| Jun-2020 | COVID-19 rapid evidence profile #12: What insights from the available evidence and jurisdictional scans can inform who should be tested for COVID-19 and how frequently, where, by whom and with what follow-up actions should they be tested? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Voorheis, P; Bhuiya, AR; Ahmad, A; Lavis, JN |
| Jun-2020 | COVID-19 rapid evidence profile #13: What pandemic-related mental health and addictions issues have emerged and what indicators and strategies can be used to monitor and address them, respectively? | Waddell, K; Wilson, MG; Bullock, HL; Evans, C; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Voorheis, P; Bhuiya, AR; Ahmad, A; Lavis, JN |
| Jun-2020 | COVID-19 rapid evidence profile #14: Where and with what impacts have shifts from in-person to virtual approaches occurred in the delivery of healthcare services in general and mental health and addictions services in particular? | Waddell, K; Bullock, HL; Evans, C; Wilson, MG; Gauvin, François-Pierre; Moat, KA; Mansilla, C; Wang, Q; Bhuiya, AR; Ahmad, A; Filbey, L; Lavis, JN |
| Jul-2020 | COVID-19 rapid evidence profile #15: What frameworks from available evidence and experiences in other countries can inform what needs to be done to plan for future waves of COVID-19? | Wilson, MG; Waddell, K; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Wang, Q; Bhuiya, AR; Voorheis, P; Ahmad, A; Gao, C; Alam, S; Lavis, JN |
| Jul-2020 | COVID-19 rapid evidence profile #16: What provider-led virtual-care services can be used to replace in-person care in hospital-based ambulatory care settings? | Wilson, MG; Waddell, K; Wang, Q; Gauvin, François-Pierre; Mansilla, C; Moat, KA; Ahmad, A; Alam, S; Bhuiya, AR; Lavis, JN |
| Aug-2020 | COVID-19 rapid evidence profile #17: What evidence could support modelling scenarios related to the reopening, operation and monitoring of schools? | Wilson, MG; Waddell, K; Moat, KA; Wang, Q; Ahmad, A; Alam, S; Bhuiya, AR; Sharma, K; Lavis, JN |
| Sep-2020 | COVID-19 rapid evidence profile #18: Which types of non-medical masks are effective in community settings for reducing the spread of COVID-19 for different populations and under different conditions? | Waddell, K; Wilson, MG; Gauvin, François-Pierre; Moat, KA; Wang, Q; Ahmad, A; Bhuiya, AR |
| Sep-2020 | COVID-19 rapid evidence profile #19: What is the risk of transmission of COVID-19 in hospital and long-term care settings, and the impacts of hospital-visitor policies? | Waddell, K; Wilson, MG; Moat, KA; Wang, Q; Gauvin, François-Pierre; Ahmad, A; Alam, S; Bhuiya, AR; Tchakerian, N; Lavis, JN |
| Apr-2020 | COVID-19 rapid evidence profile #1: What is known about approaches to and safety of conserving, reusing, and repurposing different kinds of masks? | Wilson, MG; Gauvin, François-Pierre; Waddell, K; Moat, KA; Lavis, JN |
| Oct-2020 | COVID-19 rapid evidence profile #20: What living, full or rapid reviews have been produced that provide evidence about economic and social responses to COVID-19? | Wilson, MG; Waddell, K; Moat, KA; Wang, Q; Lavis, JN |
| Oct-2020 | COVID-19 rapid evidence profile #21: What is the impact of the pandemic on substance use (particularly, alcohol and opioid use) in the population, and what policy decisions have been adopted that affect the availability and use of substances, as well as services for people who use substances? | Bullock, H; Waddell, K; Bhuiya, AR; Wilson, MG; Gauvin, François-Pierre; Moat, KA; Alam, S; Lavis, JN |
| Oct-2020 | COVID-19 rapid evidence profile #22: What is known about whether vaccine injury-compensation programs and program elements affect vaccine acceptance and uptake? | Bhuiya, AR; Waddell, K; Moat, KA; Wilson, MG; Gauvin, François-Pierre; Whitelaw, S; Alam, S; Sharma, K; Drakos, A; Lavis, JN |
| Jan-2022 | COVID-19 rapid evidence profile #27: What measures and approaches can protect the most vulnerable in hospitals when outbreaks of Omicron in hospital are becoming more common? | Wilson, MG; Bhuiya, AR; Bain, T; Al-Khateeb, S; Mansilla, C; Mehta, V; Sood, T; Soueidan, S; Rintjema, J; Waddell, K; Wang, A; Wang, Q; Wang, X; Lavis, JN |
